secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-10-21T23:59:59+00:00
Accession:  0001453687-25-000106
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics eliminates CSO role, terminates Dr. Christopher Jewell effective Nov 14, 2025
--------------------------------------------------------------------------------

- CSO position eliminated; Dr. Christopher Jewell terminated without cause effective November 14, 2025.
- Separation agreement signed Oct 20, 2025 provides 12 months salary and pro-rated bonus eligibility.
- Dr. Jewell releases all claims against the company in exchange for severance benefits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000106/0001453687-25-000106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000106/rnac-20251015.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer